Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with *KMT2Ar* or *NPM1* Alterations

<u>Christian Recher, MD, PhD1</u>; Jenny O'Nions, PhD, BMBCh, FRCPath²; Ibrahim Aldoss, MD3; Ana Alfonso Piérola, MD, PhD4; Alicia Allred⁵; Juan Manuel Alonso-Dominguez, MD, PhD6; Laura Barreyro, PhD5; Pierre Bories, MD, PhD7; Martin Curtis⁸; Nikki Daskalakis, MD5; Matteo G. Della Porta, MD9; Hartmut Döhner, MD10; Amber D'Souza, MD5; James Dugan, MD11; Jordi Esteve, MD, PhD12; Matthew Exum, MSN5; Amir T. Fathi, MD13; Pasquale L. Fedele, MBBS, PhD, FRACP, FRCPA14; Lucille Ferrante, MD, MS5; Stan Gaj, MS15; Sylvain Garciaz, MD, PhD16; Ana Garrido Diaz, MD17; Sara Garrido Paniagua, MD18; Christina Guttke, PhD5; Emmanuel Gyan, MD, PhD19; Brett Hiebert, MS²⁰; Elias Jabbour, MD²¹; Madlen Jentzsch, MD²²; Hagop M. Kantarjian, MD²¹; Marina Konopleva, MD, PhD²³; Jan Krönke, MD²⁴; Min Chul Kwon, PhD15; Christina Loefgren, MD, PhD⁵; Oliver Lomas, BMBCh, MRCP, FRCPath, DPhil²⁵; Valentina Mancini, MD²⁶; Ioannis Mantzaris, MD, MS²³; Giovanni Martinelli, MD²⁷; Daniel Morillo, MD⁶; Joseph Murphy, BSc²⁵; Kathryn Packman, PhD²⁸; Cristina Papayannidis, MD, PhD²⁹; Ulrike Philippar, PhD¹⁵; Uwe Platzbecker, MD²²; Sravanti Rangaraju, MD³⁰; Christoph Röllig, MD, MSci³¹; Olga Salamero, MD1⁸; Madhu Sanga, PhD³²; Tim Sauer, MD³³; Emma Searle, MD, PhD³⁴; Natalia Tovar, MD, PhD¹²; Trevor Tucker, BS⁵; Nicolas Vallet, MD, PhD¹⁹; Lachlin Vaughan, MD³⁵; Gala Vega, MD⁶; Paresh Vyas, DPhil, FRCP, FRCPath, FMedSci³⁶; Andrew H. Wei, MBBS, PhD³⁷

¹University Cancer Institute Toulouse Oncopole, Toulouse, France; ²University College London Hospital NHS Foundation Trust, London, UK; ³City of Hope National Medical Center, Duarte, CA, USA; ⁴Clínica Universidad de Navarra, Navarra, Spain; ⁵Janssen Research & Development, LLC, Spring House, PA, USA; ⁶Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain; ⁷Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France; ⁸Janssen Research & Development, LLC, Durham, NC, USA; ⁹IRCCS Humanitas Research Hospital and Humanitas University, Milan, Italy; ¹⁰ Ulm University Hospital, Ulm, Germany; ¹¹Novant Health Cancer Institute, Winston Salem, NC, USA; ¹²Hospital Clínic de Barcelona, Barcelona, Spain; ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ¹⁴Monash Health and School of Clinical School, Boston, MA, USA; ¹⁴Monash Health and School of Clinical School, Boston, MA, USA; ¹⁴Monash Health and School of Clinical School, Boston, MA, USA; ¹⁴Honsh Health and School of Clinical School, Boston, MA, USA; ¹⁴Honsh Health and School of Clinical School, Boston, MA, USA; ¹⁴Monash Health and School of Clinical School, Boston, MA, USA; ¹⁴Monash Health and School of Clinical School, Boston, MA, USA; ¹⁴Honsh Health Cancer, ¹⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ¹⁸University Hospital Vall d'Hebron, and Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain; ¹⁹Centre Hospitalier Universitaire de Tours, Tours, France; ²⁰IQVIA, Winnipeg, MB, Canada; ²¹MD Anderson Cancer Center, University of Texas, Houston, TX, USA; ²²Universitäkskinikum Leipzig, Leipzig, Germany; ²³Albert Einstein College of Medicine, Bronx, NY, USA; ²⁴Charité - Universitätsmedizin Berlin, Germany; ²⁵Janssen Research & Development, LLC, High Wycombe, UK; ²⁶ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ³⁰University of Alabama, Birmingham, AL, USA; ³¹Universitätsklinikum TU Dresden, Dere

Presented by C Recher at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 7-10, 2024; San Diego, CA, USA

https://www.congresshub.com/ ASH2024/Oncology/EarlyAssets/Recher


Scan the QR code

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



Bleximenib Combined With Intensive Chemotherapy in ND-AML Background


- Newly diagnosed (ND) AML is a genetically heterogeneous disease with a median 5-year overall survival of ~30%^{1,2}
- High intensity chemotherapy (IC), comprising '7+3' with cytarabine consolidation remains a cornerstone
 of therapy, in those 'fit' enough to undergo such therapy
- Bleximenib (JNJ-75276617) is a potent, selective inhibitor of the menin-KMT2A complex³
- Activity has been observed in KMT2Ar or NPM1m AML when given either as monotherapy or in combination^{4,5}



'7+3', cytarabine + anthracycline (daunorubicin or idarubicin); AML, acute myeloid leukemia; IC, intensive chemotherapy; *KMT2Ar, KMT2A*-rearranged; ND, newly diagnosed; *NPM1m, NPM1*-mutated.
1. Chandra Kumar C. *Genes Cancer* 2011;2:95–107. 2. American Cancer Society. Cancer Facts & Figures 2024. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf (accessed November 2024). 3. Kwon M, et al. Presented at ASH; December 10–13, 2022; New Orleans, LA, USA. Poster 2637.
4. Jabbour E at al. Presented at ASH; December 9–12, 2022; San Diego, California, USA. Oral presentation 616. 5. Wei AH, et al. Presented at EHA; June 13–16, 2024; Madrid, Spain. Abstract S133.




Bleximenib Combined With Intensive Chemotherapy in ND-AML Study Design



ALE1002

RP2D, recommended Phase 2 dose; R/R, relapsed/refractory; VEN, venetoclax.

Bleximenib Combined With Intensive Chemotherapy in ND-AML Dosing Schedule



Key Considerations

- Age \geq 18 and fit for intensive chemotherapy
- Bleximenib BID commences on C1D4 without step-up dosing
- '7+3' dosing with anthracycline (daunorubicin or idarubicin) as per SOC / institutional guidelines with single cycle and reinduction if remission not achieved; consolidation begins for responders upon count recovery
- Continuation therapy available in absence of allograft
- Bleximenib PK exposures in combination studies similar to monotherapy study

NCT05453903

'7+3', cytarabine + anthracycline (daunorubicin or idarubicin); BID, twice daily; C, cycle; D, day; ND, newly-diagnosed; PK, pharmacokinetic; SOC, standard of care.

Presented by C Recher at the American Society of Hematology (ASH) 2024 Annual Meeting & Exposition; December 7–10, 2024; San Diego, California, USA



ALE1002

Bleximenib Combined With Intensive Chemotherapy in ND-AML Baseline Demographics and Characteristics – Safety Group

Characteristic	Overall population (N=28)	
Age, median (range), years	58 (24–70)	
Female, n (%)	15 (54%)	
ECOG PS, n (%)		
0	10 (35.7%)	
1	17 (60.7%)	
2	1 (3.6%)	
Median leukocyte (range) x 10 ⁹ /L	3.22 (0.86–20.08)	
Median bone marrow blast (range), %	51% (2–98)	
is disc		

Characteristic	Overall population (N=28)	
Genetic alterations, n (%)		
KMT2A	13 (46%) [<i>KMT2Ar</i> n=9 (32%)]	
NPM1	15 (54%)	
Relevant co-mutations (in at least 4 pts)		
DNMT3a	6	
FLT3 (ITD:TKD)	6 (3,3)	
TET2	4	



ALE1002

Data sources: TSIDEM01BBCOHORTC1, TSIDEM02BBCOHORTC1.

Data cut-off date: October 9, 2024.

AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; ND, newly-diagnosed; NPM1m, NPM1-mutated.

Bleximenib Combined With Intensive Chemotherapy in ND-AML Safety Profile – TEAEs (Regardless of Relatedness)

TEAE (N=28 participants)	Any grade	Grade ≥3
Total, n (%)	28 (100)	26 (93)
Hematologic AEs		
Thrombocytopenia	19 (68)	19 (68)
Febrile neutropenia	18 (64)	17 (61)
Neutropenia	15 (54)	15 (54)
Anemia	16 (57)	15 (54)
Leukopenia	9 (32)	9 (32)
Nonhematologic AEs		- Pull
Pneumonia	8 (29)	6 (21)
Sepsis	4 (14)	4 (14)
Nausea	15 (54)	3 (10)
Stomatitis	11 (39)	o ^o 3 (10)
GGT Increased	5 (18)	4 (14)
Hypotension	6 (21)	3 (10)

andisnot	Bleximenib 30 to 100 mg BID + '7+3' N=28	
Count Recovery in Induction	Median days (range)	
Days to platelet count recovery (50x10 ⁹ /L)	32 (22–74)	
Days to neutrophil count recovery (0.5x10 ⁹ /L)	33 (25–57)	

Key Observations

- No DS or DLTs observed to date
- Safety profile consistent with intensive chemotherapy backbone therapy
- No clinically significant myelosuppression observed in induction




Data sources: TSFAE02BBCOHORTC1, TSFAE24BBCOHORTC1, TSFREC01

Data cut-off date: October 9, 2024.

AE, adverse event; AML, acute myeloid leukemia; BID, twice daily; DLT, dose-limiting toxicity; DS, differentiation syndrome; GGT, gamma-glutamyl transferase; ND, newly diagnosed; TEAE, treatment-emergent adverse event.

Bleximenib Combined With Intensive Chemotherapy in ND-AML Safety Profile: Key Adverse Events Related to Bleximenib

ND Fit AML (Cohort C1)



Key Observations

No DS or DLTs observed to date

- DS rate with bleximenib in combination lower than bleximenib monotherapy
- No QTc prolongation signal identified with bleximenib
- Bleximenib dose reductions: 2 (7%)
- Bleximenib dose discontinuations: 2 (7%)




ALE1002

Data sources: TSFAE02BB, TSFAE02BBCOHORTC1 ; Data cut-off date: October 9, 2024.

'7+3', cytarabine + anthracycline (daunorubicin or idarubicin); AML, acute myeloid leukemia; DLT, dose-limiting toxicity; DS, differentiation syndrome; ND, newly diagnosed; QTc(F), corrected QT interval (Friderica); TRAE, treatment-related adverse event.

Bleximenib Combined With Intensive Chemotherapy in ND-AML Safety and Efficacy Populations



ALE1002

AML, acute myeloid leukemia; BID, twice daily; ITT, intent-to-treat; KMT2Ar, KMT2A-rearranged; NPM1m, NPM1-mutated; pt, participant; R/R, relapsed/refractory.

Bleximenib Combined With Intensive Chemotherapy in ND-AML Preliminary ITT Efficacy

Efficacy Parameter	Bleximenib (<u>></u> 50 mg BID) + '7+3' (N=21)		
ORR (≥PR), n (%)	95% (20/21)		
Composite BOR, n (%)			
cCR (CR/CRh/CRi)	86% (18/21)		
CR/CRh	81% (17/21)		
CR	76% (16/21)		
MLFS + PR	9.5% (2/21)		
Mutation-specific composite BOR, n (%)	<i>KMT2Ar</i> (N=8)	NPM1m (N=13)	
ORR, n (%)	7 (88%)	5 13 (100%)	
CR/CRh	7 (88%)	10 (77%)	
MLFS + PR	0 district	2 (15%)	

Responses were investigator-assessed per modified ELN 2017 criteria (AML)

Data sources: TEFRS02BBB, TEFRS02EBB, TEFRS02FBB. Data cut-off date: October 9, 2024.

*As reported by investigators based on screening genetic data

'7+3', cytarabine + anthracycline (daunorubicin or idarubicin); AML, acute myeloid leukemia; BID, twice daily; BOR, best overall response; C, cycle; CR, complete response; CRh, CR with partial haematological recovery; CRi, complete remission with incomplete recovery; ELN, European LeukemiaNet; ITT, intent-to-treat; *KMT2Ar*, *KMT2A* rearranged; MLFS, morphologic leukemia-free state; MRD, minimal residual disease; ND, newly diagnosed;

NPM1m, NPM1-mutated; ORR, overall response rate; PR, partial response.


Key Observations

- Similar response rates observed in both KMT2Ar and NPM1m AML
- ELN 2022 Risk stratification* (efficacy cohort; n=21)
 - Favourable 10 (48%)
 - Intermediate 8 (38%)
- Adverse 3 (14%)
- Local MRD status among tested responders (n=9)
 - Bleximenib 50 mg BID + '7+3': 2/3 MRD-
 - Bleximenib 100 mg BID + '7+3': 6/6 MRD-



Bleximenib Combined With Intensive Chemotherapy in ND-AML Duration of Treatment in Responders

≥ 50 mg BID Bleximenib + High Intensity Chemotherapy



Data cut-off date: October 9, 2024. N=20: responders only. AML, acute myeloid leukemia; BID, twice daily; *KMT2Ar, KMT2A* rearranged; ND, newly diagnosed; pt, participant.

Presented by C Recher at the American Society of Hematology (ASH) 2024 Annual Meeting & Exposition; December 7–10, 2024; San Diego, California, USA


Key Observations

- 3 pts proceeded to allograft (all *KMT2Ar*)
- 13 pts active; 9 in continuation therapy with bleximenib monotherapy
- 4 pts discontinued
- No relapse or mortality observed



Bleximenib Combined With Intensive Chemotherapy in ND-AML Conclusions

- Safety data demonstrate that bleximenib is combinable with SOC IC for ND fit AML
 - No DS or DLTs observed to date DS rate with bleximenib in combination with '7+3' lower than bleximenib monotherapy
 - No clinically significant myelosuppression observed
 - No QTc prolongation signal identified
- Preliminary efficacy in ND AML high response rates comparable across KMT2Ar or NPM1m with bleximenib and IC
 - -13 pts ongoing and 9 in continuation therapy
- Exploration ongoing of bleximenib in combination with AML-directed therapies (ALE1002: NCT05453903), supportive of future Phase 3 studies
- Phase 2 bleximenib monotherapy cAMeLot-1 study ongoing (NCT04811560)





Bleximenib Combined With Intensive Chemotherapy in ND-AML Acknowledgements

- We thank the participants who are taking part in this study and their caregivers, the physicians and nurses who care for them, the staff at the study sites, and the staff involved in data collection and analyses
- This study was funded by Janssen Research & Development, LLC
- Medical writing support was provided by Ashfield MedComms and funded by Janssen Global Services, LLC



https://www.congresshub.com/ ASH2024/Oncology/EarlyAssets/Recher

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

